1ADO
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Adalta Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Adalta Limited - Option Expiring 30-Jun-2021
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.04
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in 1ADO
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in 1ADO
N/A
1ADO investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in 1ADO also invest in...
Want more shares? Try these...
1ADNB
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-08-22. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies.